Shared on08 Oct 25Fair value Increased 9.32%
Guardant Health's analyst price target has been raised from approximately $62 to $68 per share. Analysts cite accelerating revenue growth, improved operating margins, and ongoing commercial and strategic momentum as key factors behind the upward revision.
Shared on23 Sep 25Fair value Increased 1.75%
Guardant Health’s price target was raised as analysts cited strong revenue momentum, clinical data underscoring leadership in liquid biopsy, and Q2 outperformance across key segments, resulting in a new consensus price target of $62.41. Analyst Commentary Bullish analysts cite strong revenue momentum, with new products and expanded indications expected to drive 30% annual growth through 2028, outpacing peers.
Shared on24 Apr 25Fair value Decreased 0.85%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 0.24%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 4.33%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 5.20%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.